647 related articles for article (PubMed ID: 28147705)
1. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
Jacobson KB; Niccolai L; Mtungwa N; Moll AP; Shenoi SV
AIDS Care; 2017 Jul; 29(7):936-942. PubMed ID: 28147705
[TBL] [Abstract][Full Text] [Related]
2. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
Lester R; Hamilton R; Charalambous S; Dwadwa T; Chandler C; Churchyard GJ; Grant AD
AIDS; 2010 Nov; 24 Suppl 5():S45-8. PubMed ID: 21079427
[TBL] [Abstract][Full Text] [Related]
3. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study.
Mindachew M; Deribew A; Memiah P; Biadgilign S
Pan Afr Med J; 2014; 17():26. PubMed ID: 24932337
[TBL] [Abstract][Full Text] [Related]
4. The role of agency in the implementation of Isoniazid Preventive Therapy (IPT): Lessons from oMakoti in uMgungundlovu District, South Africa.
Boffa J; Mayan M; Ndlovu S; Mhlaba T; Williamson T; Sauve R; Fisher D
PLoS One; 2018; 13(3):e0193571. PubMed ID: 29513719
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
Karanja M; Kingwara L; Owiti P; Kirui E; Ngari F; Kiplimo R; Maina M; Masini E; Onyango E; Ngugi C
PLoS One; 2020; 15(12):e0234588. PubMed ID: 33264300
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
Ngugi SK; Muiruri P; Odero T; Gachuno O
BMC Infect Dis; 2020 Apr; 20(1):294. PubMed ID: 32664847
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.
Tram KH; Mwangwa F; Atukunda M; Owaraganise A; Ayieko J; Plenty A; Kwariisima D; Clark TD; Petersen ML; Charlebois ED; Kamya MR; Chamie G; Havlir DV; Marquez C;
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):e115-e117. PubMed ID: 28885271
[No Abstract] [Full Text] [Related]
8. Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
Hunter OF; Kyesi F; Ahluwalia AK; Daffé ZN; Munseri P; von Reyn CF; Adams LV
BMC Infect Dis; 2020 Oct; 20(1):738. PubMed ID: 33028260
[TBL] [Abstract][Full Text] [Related]
9. The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini.
Grande SW; Adams LV; Maseko TSB; Talbot EA; deGijsel D; Mikal J; Simelane ZZ; Achili A; Mkhontfo M; Haumba SM
PLoS One; 2020; 15(5):e0232841. PubMed ID: 32469990
[TBL] [Abstract][Full Text] [Related]
10. To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.
Reddy MM; Thekkur P; Ramya N; Kamath PBT; Shastri SG; Kumar RBN; Chinnakali P; Nirgude AS; Rangaraju C; Somashekar N; Kumar AMV
Glob Health Action; 2020; 13(1):1704540. PubMed ID: 31937200
[No Abstract] [Full Text] [Related]
11. Survey of isoniazid preventive therapy in South Africa, 2011.
Chehab JC; Vilakazi-Nhlapo K; Vranken P; Peters A; Klausner JD
Int J Tuberc Lung Dis; 2012 Jul; 16(7):903-7. PubMed ID: 22583688
[TBL] [Abstract][Full Text] [Related]
12. Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
Tram KH; Mwangwa F; Chamie G; Atukunda M; Owaraganise A; Ayieko J; Jain V; Clark TD; Kwarisiima D; Petersen ML; Kamya MR; Charlebois ED; Havlir DV; Marquez C;
AIDS Care; 2020 Jan; 32(1):119-127. PubMed ID: 31181961
[TBL] [Abstract][Full Text] [Related]
13. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
[TBL] [Abstract][Full Text] [Related]
14. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
15. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
Frigati LJ; Kranzer K; Cotton MF; Schaaf HS; Lombard CJ; Zar HJ
Thorax; 2011 Jun; 66(6):496-501. PubMed ID: 21460373
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Golub JE; Pronyk P; Mohapi L; Thsabangu N; Moshabela M; Struthers H; Gray GE; McIntyre JA; Chaisson RE; Martinson NA
AIDS; 2009 Mar; 23(5):631-6. PubMed ID: 19525621
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.
Wambiya EOA; Atela M; Eboreime E; Ibisomi L
BMJ Open; 2018 Dec; 8(12):e024286. PubMed ID: 30573488
[TBL] [Abstract][Full Text] [Related]
18. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Munseri PJ; Talbot EA; Mtei L; Fordham von Reyn C
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1037-41. PubMed ID: 18713501
[TBL] [Abstract][Full Text] [Related]
19. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries.
Charles MK; Lindegren ML; Wester CW; Blevins M; Sterling TR; Dung NT; Dusingize JC; Avit-Edi D; Durier N; Castelnuovo B; Nakigozi G; Cortes CP; Ballif M; Fenner L;
PLoS One; 2016; 11(4):e0153243. PubMed ID: 27073928
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
Semu M; Fenta TG; Medhin G; Assefa D
BMC Infect Dis; 2017 Jan; 17(1):5. PubMed ID: 28049455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
